Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MoneyHero

    MCap

    USD60m

    Last close

    USD2.35

    ▲ 0.55 (30.56%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

OSE Immunotherapeutics – executive interview with Nicolas Poirier, CEO

OSE Immunotherapeutics – executive interview with Nicolas Poirier, CEO

OSE Immunotherapeutics — 2 videos in collection

More on this equity

OSE Immunotherapeutics (OSE) is developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharmaceutical companies. These therapies address numerous different indications and include Tedopi, OSE-127 and OSE-279.

In this interview, CEO Dr Nicolas Poirier provides highlights of the key therapies in development for both immuno-oncology and immuno-inflammation, including:

  • the preparation for a confirmatory pivotal Phase III trial for OSE’s lead asset Tedopi in non-small cell lung cancer;
  • the ongoing Phase I/II dose-escalation trial of OSE-279, an anti-PD1 monoclonal antibody ICI therapy designed for blockade of both PD-L1 and PD-L2; and
  • the ongoing Phase II clinical trial of Lusvertikimab, OSE’s most advanced immuno-inflammation asset.
< Previous
Next >

You may also be interested in these:

Healthcare

OSE Immunotherapeutics - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free